Kevin

,
A tale of racial bias that delayed a diagnosis

Matthew

,
Author, composer and life-long learner, Matthew lives with peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD).

Christopher

,
Hear from Christopher as he describes his journey with focal segmental glomerulosclerosis (FSGS), from diagnosis and day-to-day with this rare kidney disease, to his work with NephCure Kidney International.
RARE-X logo

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.

Read the full press release >

Lindsey

,
At the 2019 ERA-EDTA Congress in Budapest, the company hosted a panel discussion led by people living with rare glomerular disease. Lindsay, a 17-year-old scholar, athlete and musician, shared about her journey with focal segmental glomerulosclerosis (FSGS).

Rare Disease Diversity Coalition Formed To End Racial Disparities In Rare Disease Diagnosis, Research And Treatment

On February 23, 2021, the Black Women’s Health Imperative (BWHI) held the first public meeting of the Rare Disease Diversity Coalition (RDDC) with more than 200 rare disease community members joining together to endorse an ambitious platform of 10 initiatives to achieve tangible solutions to address issues, including delays in diagnosis and treatment for diverse patients. We’re proud to work closely with the leaders of the BWHI to spearhead the formation of the RDDC.
RARE-X logo

RARE-X Announces Patient Community Data Collection, Sharing, and Platform Enhancements with Support from Travere

On February 23, 2021, the nonprofit organization RARE-X announced plans to expand its work helping patient groups collect structured, standardized research-ready data that will better support the development of future treatments. This foundational work is made possible through a funding commitment from Travere Therapeutics.

Lillie

,
Lillie – living with IgA nephropathy, and her mom Carrie, talk about life with rare kidney disease.

Paul

,
Paul, living with cystinuria, talks about the critical role of water – both in his profession and for managing his rare condition.
RARE-X logo

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Read the full press release >